glp 1 agonist metformin glp-1_analogs [TUSOM Glucagon-like peptide-1 receptor: mechanisms and

Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis

It acts on receptors in the hypothalamus and brainstem to promote satiety and reduce food intake

Endogenous GLP-1, at physiological picomolar levels, primarily engages the PLC/PKC pathway, which is critical for natural regulation

In addition, there are multiple other drugs currently under development, including several oral drugs such as Orforglipron from Eli Lilly and Danuglipron from Pfizer, as well as further dual and triple receptor agonists

Dipeptidyl Peptidase 4 (DPP-4) Inhibitors are the fastest growing segment in the Glucagon-like Peptide 1 (GLP-1) market, attributed to their convenience and ease of use for patients who prefer oral medications or have aversions to injections

(September 2015)